COMPASS Pathways plc (CMPS)
| Market Cap | 1.66B +540.5% |
| Revenue (ttm) | n/a |
| Net Income | -192.36M |
| EPS | -3.08 |
| Shares Out | 134.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,984,266 |
| Open | 14.50 |
| Previous Close | 13.31 |
| Day's Range | 12.63 - 14.60 |
| 52-Week Range | 3.50 - 15.40 |
| Beta | 2.49 |
| Analysts | Strong Buy |
| Price Target | 24.47 (+98.94%) |
| Earnings Date | Jul 30, 2026 |
About CMPS
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in L... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for CMPS stock is "Strong Buy." The 12-month stock price target is $24.47, which is an increase of 98.94% from the latest price.
News
Compass Pathways’ COMP360 treatment featured in published PTSD trial
Compass Pathways (CMPS) announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients wi...
Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
Psychedelic: Compass Pathways reports six-month data for psilocybin drug
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, drug delivery evaluation and last patient dosing. COMPASS PATHWAYS REPO...
Evercore upgrades Compass Pathways to Outperform, views approval as likely
As previously reported, Evercore ISI upgraded Compass Pathways (CMPS) to Outperform from In Line with a price target of $21, up from $8. The crux of the firm’s previous downgrade…
Compass Pathways upgraded to Outperform from In Line at Evercore ISI
Evercore ISI upgraded Compass Pathways (CMPS) to Outperform from In Line.
Compass Pathways price target raised to $21 from $14 at Stifel
Stifel analyst Paul Matteis raised the firm’s price target on Compass Pathways (CMPS) to $21 from $14 and keeps a Buy rating on the shares. Blinded durability data for COMP360…
Wolfe Research says Compass Pathways pullback an attractive entry point
Wolfe Research analyst Rudy Li said COMP006’s durable 26-week data, improved responder/remission rates, and clean safety profile keep the NDA/1H27 launch on track. The firm views today’s pullback as a...
Compass Pathways announces six-month data from COMP006 trial
Compass Pathways (CMPS) announced the 26-week results from its second ongoing Phase 3 COMP006 trial of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression w...
Compass new data validates COMP360 durability profile, says Morgan Stanley
Morgan Stanley notes that Compass Pathways (CMPS) reported COMP006 Part B 26-week data from its second Phase 3 pivotal trial of COMP360 in treatment-resistant depression, further bolstering the rapid ...
Compass Pathways data strengthens launch prospects, says Oppenheimer
Oppenheimer maintains an Outperform rating and $20 price target on shares of Compass Pathways (CMPS), telling investors in a research note that the Phase 3 COMP006 26-week data reinforce the…
Compass Pathways study data supports benefit of second dose, says Stifel
Stifel reiterates a Buy on Compass Pathways (CMPS) following 6-month blinded Phase 3 data for COMP360 in treatment-resistant depression, telling investors in a research note that results support the b...
COMPASS Pathways Transcript: Study result
COMP360 showed rapid and durable efficacy in highly treatment-resistant depression, with about 40% of patients achieving meaningful response and a favorable safety profile through 26 weeks. Regulatory review is underway, with anticipated U.S. launch in 2027 and strong stakeholder enthusiasm for this differentiated treatment.
COMPASS Pathways Press release: Study result
COMPASS Pathways issued a press release on July 7, 2026, disclosing material business information to investors.
COMPASS Pathways Slides: Study result
COMPASS Pathways has posted slides in relation to its latest quarterly earnings report, which was published on July 7, 2026.
Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced tod...
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
Issued on behalf of Helus Pharma™ Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., says its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major...
Compass Pathways price target raised to $20 from $18 at Canaccord
Canaccord raised the firm’s price target on Compass Pathways (CMPS) to $20 from $18 and keeps a Buy rating on the shares. The firm said they believe shares are significantly…
COMPASS Pathways PLC put volume heavy and directionally bearish
Bearish flow noted in COMPASS Pathways (CMPS) PLC with 1,149 puts trading, or 2x expected. Most active are Nov-26 6 puts and Aug-26 11 puts, with total volume in those…
3 Companies Redefining Healthcare Innovation
The Healthcare Technology and Innovation index (HTEC) was launched back in 2019 with a specific purpose in mind: to allow investors to participate in the evolution of healthcare needed to address crit...
Why Trump Is Pushing Psychedelics To Treat Mental Illness
The Trump administration is pushing to fast-track psychedelic drug approvals as his economic approval ratings hit record lows, marking a sharp reversal from his first term stance on drugs. Three compa...
Why Trump reversed course to fast-track psychedelic drugs for mental healthcare
President Donald Trump aims to fast-track research into psychedelic therapy for conditions like post traumatic stress disorder and depression in a break from his first administration policy. Advocates...
Compass Pathways Elects Kathleen Tregoning to Board of Directors
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
COMPASS Pathways Transcript: RBC Capital Markets Global Healthcare Conference 2026
COMP360 psilocybin shows rapid, durable efficacy in treatment-resistant depression, with regulatory review and commercialization progressing swiftly. Infrastructure and site readiness are robust, and expansion into PTSD is supported by promising early data and VA collaboration.